



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Moldenhauer, Maxine G. Examiner:  
Serial No.: 10/849,282 Art Unit: 1614  
Filed : May 19, 2004 Confirmation No. 6646  
For : Novel Topical Steroid Cream Formulations

**EXPRESS MAIL**  
August 10, 2004

Taro Pharmaceuticals, U.S.A. Inc.  
5 Skyline Drive  
Hawthorne, NY 10532

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450


### **Request for Corrected Filing Receipt Under 37 C.F.R. § 1.78 (ii)** **Filing Date Granted**

Dear Sirs:

Enclosed herewith is a Preliminary Amendment and Declaration and Power of Attorney of the Inventor for U.S. Application No. 10/849,282 filed on May 19, 2004, citing the proper claim to the priority benefit of U.S. Provisional Application No. 60/473,313 filed on May 23, 2003. I request that the Filing Receipt be corrected to reflect the Domestic Priority Data.

No fee is due because as the reference to a priority application was made within four months of the filing of the later filed application (U.S. Application No. 10/849,282). 37 C.F.R. In the event that any fee is due, however, The Patent and Trademark Office is authorized hereby to charge Deposit Account No. 502,392 for any such fee due in connection with this Preliminary Amendment.

Respectfully submitted,

  
\_\_\_\_\_  
Donna A. Robertson-Chow  
Reg. No. 47,030



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/849,282	05/19/2004	1614	770	1032-US2		5	2

35159  
 TARO PHARMACEUTICALS  
 5 SKYLINE DRIVE  
 HAWTHORNE, NY 10532

CONFIRMATION NO. 6646  
 FILING RECEIPT



\*OC000000013266252\*

Date Mailed: 07/19/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Maxine G. Moldenhauer, Residence Not Provided; Action, Canada

Domestic Priority data as claimed by applicant — May 23, 2003 to  
 U.S. 60/473,313

**Foreign Applications**

If Required, Foreign Filing License Granted: 07/16/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

**Title**

Novel topical steroid cream formulations

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).